Simplifying Global Compliance
FDAnews Drug Daily Bulletin
UCB Gets Complete Response Letter From FDA Regarding Neupro
April 26, 2010
UCB SA has received a complete response letter from the U.S. Food and Drug Administration (FDA) recommending reformulation of Neupro before making it available in the U.S. market for the treatment of Parkinson's disease and restless legs syndrome.
Copyright ©2017. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing